Abbott Laboratories 10-Q Summary: Period Ended June 30, 1995
Business Context and Reporting Period
This is an unaudited quarterly report (Form 10-Q) for Abbott Laboratories, an Illinois corporation, covering the three and six months ended June 30, 1995. The company operates primarily in pharmaceutical, nutritional, hospital, and laboratory products. As of July 31, 1995, there were 793,539,326 common shares outstanding.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended June 30, 1995 | 6 Months Ended June 30, 1995 |
|---|---|---|
| Net Sales | $2,500,310 | $5,024,707 |
| Net Earnings | $424,030 | $841,284 |
| Earnings Per Share | $0.53 | $1.05 |
| Operating Earnings | $594,650 | $1,184,129 |
| Net Cash from Operating Activities | N/A | $1,035,215 |
| Cash and Cash Equivalents (End of Period) | $254,395 | $254,395 |
| Short-term Borrowings & Current Debt | $829,594 | $829,594 |
| Long-Term Debt | $435,730 | $435,730 |
Margins: Gross profit margin was 56.6% for the second quarter and 56.7% for the first six months of 1995. Research and development expenses represented 11.5% of net sales in Q2 and 10.6% for the six-month period.
Material Changes vs. Prior Period
- Sales Growth: Net sales increased 13.4% in Q2 and 13.7% for the six months ended June 30, 1995, compared to the same periods in 1994.
- Earnings Growth: Net earnings rose 12.6% in Q2 and 13.3% for the six-month period. Earnings per share increased 15.2% and 15.4%, respectively.
- Expense Increases: Selling, general, and administrative expenses increased 13.6% (Q2) and 17.1% (6 months), driven by new product support, charitable contributions, and litigation charges. R&D expenses increased due to concentration on pharmaceutical and diagnostic products.
- Currency Impact: International sales were favorably affected by a weaker U.S. dollar (7.8% in Q2, 6.4% year-to-date). Net foreign exchange losses decreased significantly compared to the prior year.
- Share Repurchases: The company purchased and retired 10,710,000 shares during the first six months at a cost of $396 million.
Outlook, Risks, and Management Commentary
- Liquidity: The company maintains AAA (S&P) and Aa1 (Moody's) bond ratings. It has $400 million in unused domestic lines of credit. Management expects annual operating cash flow to approximate or exceed capital expenditures and dividends.
- Debt Issuance: In May 1995, the company issued $150 million in senior debt securities to retire short-term borrowings and fund share repurchases. An additional $150 million may be issued under the existing registration.
- Legal Proceedings: Significant litigation remains pending, including 20 antitrust suits regarding infant formula marketing and 122 suits regarding prescription pharmaceutical pricing. Management believes the ultimate disposition will not have a material adverse effect on financial position.
- Regulatory Risks: The company faces potential legislative changes regarding health care payment and delivery, which could reduce prices or price increases for medical products.
Investor Verification Checklist
- Verify the status and potential financial impact of the 122 pending antitrust suits regarding prescription drug pricing.
- Monitor the outcome of the Nestle Food Company antitrust appeal and other infant formula litigation.
- Assess the impact of potential U.S. and international health care legislation on pricing power.
- Review the sustainability of gross profit margins given inflation and higher manufacturing capacity costs.
- Confirm the company's ability to maintain its share repurchase program while managing capital expenditures and debt obligations.